Raali Rohith, Suresh P K
Department of Biotechnology, School of Biosciences & Technology, VIT University, Vellore Dt. PIN:632014, India.
Department of Biomedical Sciences, School of Biosciences & Technology, VIT University, Vellore Dt. PIN: 632014, India.
Curr Gene Ther. 2025;25(4):497-517. doi: 10.2174/0115665232351747241113050243.
Glioblastoma is a malignant manifestation of a solid brain tumour with a very dismal prognosis due to an overall median survival of 14 months. The currently administered Standard treatment plan, the STUPP regimen, is not very effective in tackling this neoplasia. A major concern that affects the development of new drug formulations, specifically for Glioma, is the inherent sub-clonal heterogeneity, which includes the dynamic and intricate nature of the Tumour Microenvironment (TME). Targeting the cellular niche using personalized medication for glioma specifically gene therapy, seems to be promising, with most studies in preclinical models yielding optimistic results. This paper analyses the great headways made in glioma gene therapy in the last 10 years while looking into different therapeutic strategies. That said, certain challenges do plague the clinical use of gene therapy which have been highlighted in the hopes that future researchers will address these concerns and further propel gene therapy in its journey from the Lab to the bedside.
胶质母细胞瘤是一种实体脑肿瘤的恶性表现，由于总体中位生存期为14个月，其预后非常糟糕。目前实施的标准治疗方案，即STUPP方案，在应对这种肿瘤形成方面效果不佳。影响新药物制剂（特别是针对胶质瘤的制剂）开发的一个主要问题是固有的亚克隆异质性，其中包括肿瘤微环境（TME）的动态和复杂性质。使用针对胶质瘤的个性化药物（特别是基因治疗）靶向细胞生态位似乎很有前景，大多数临床前模型研究都产生了乐观的结果。本文分析了过去10年胶质瘤基因治疗取得的重大进展，同时探讨了不同的治疗策略。也就是说，基因治疗的临床应用确实面临一些挑战，本文对此进行了强调，希望未来的研究人员能够解决这些问题，并进一步推动基因治疗从实验室走向临床应用。
